- This event has passed.
CBA 23rd Annual Conference
2018年5月2日 @ 9:00 AM - 10:00 PM EDT
Introduction of confirmed distinguished speaker
Brilliant Achievement Award Presentation
Richard Pazdur, M.D.
Director, Oncology Center of Excellence
United States FDA
Pazdur博士现为FDA肿瘤卓越中心主任, 这是FDA为更好地满足肿瘤患者需求首次针对一个疾病领域成立的横跨药品, 生物制品和医疗器械的中心, 以增强各个中心之间的协作, 加速抗肿瘤类医疗产品的临床审评。这是美国前副总统拜登提出的癌症“登月计划”的一部分。Pazdur博士作为部门主管, 负责领导开发工作并执行综合监管方法以加强中心的跨中心协调肿瘤产品临床审查。
Pazdur博士发表了600多篇文章, 书籍章节和摘要。2015年“财富”杂志将他评为全球50位最伟大的领导人之一。2016年被提名为马萨诸塞州总医院癌症中心的“杰出百人“名单。在2017年，彭博社将他列为最有影响50人中的一员。他获得的其他许多专业奖项包括：美国临床肿瘤协会公共服务奖(2009和2013年), 美国癌症研究协会杰出公共服务奖(2015), 全国癌症幸存者公共领导奖(2015), LUNGevity基金会希望奖(2015), 美国临床药理学会的加里尼尔奖(2018)和国家罕见疾病出色组织影响奖(2018)。[sam_pro id=0_3 codes=”true”]
Richard Pazdur, M.D. is the director of the FDA’s Oncology Center of Excellence (OCE), which leverages the combined skills of FDA’s regulatory scientists and reviewers with expertise in drugs, biologics, and devices to expedite the development of novel cancer products. In this role, Dr. Pazdur is responsible for leading the effort to develop and execute an integrated regulatory approach to enhance the cross-center coordination of oncology product clinical review.
Dr. Pazdur previously served as director of the Office of Hematology and Oncology Products (OHOP) in the FDA’s Center for Drug Evaluation and Research. This Office was formed in 2005 to consolidate the review of drugs and therapeutic biologics for the diagnosis, treatment, and prevention of cancer, as well as the review of drugs and therapeutic biologics for hematologic diseases and for medical imaging. As OHOP director, Dr. Pazdur facilitated coordination of oncology activities across all FDA Centers and ensured an ongoing outreach and collaboration between FDA, the National Cancer Institute, and other cancer-related organizations within and outside of the government. Dr. Pazdur was the director of the FDA’s Division of Oncology Drug Products from September 1999 to May 2005.
Prior to joining the FDA, Dr. Pazdur was a professor of medicine at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. During his tenure at M. D. Anderson Cancer Center, from 1988 to 1999, Pazdur held administrative positions of assistant vice president for academic affairs, associate director of clinical trials administration (Division of Medicine) and director of educational programs (Division of Medicine). From 1982 to 1988, Dr. Pazdur served on the faculty of Wayne State University, Detroit, Michigan.
Dr. Pazdur received his bachelor’s degree from Northwestern University (Evanston, Illinois), his M.D. from Loyola Stritch School of Medicine (Maywood, Illinois), and completed clinical training at Rush-Presbyterian St. Luke’s Medical Center (Chicago, Illinois) and the University of Chicago Hospitals and Clinics.
Dr. Pazdur has published more than 600 articles, book chapters, and abstracts. In 2015, Fortune magazine named him one of the 50 World’s Greatest Leaders. In 2016, Dr. Pazdur was named to Massachusetts General Hospital Cancer Center’s “The One Hundred” list. In 2017, Bloomberg honored him as one of the first Bloomberg 50. He is the recipient of many other professional awards, including: the American Society of Clinical Oncology Service Recognition Award (2009) and Public Service Award (2013); the American Association for Cancer Research Distinguished Public Service Award (2015); the National Coalition for Cancer Survivorship Public Service Leadership Award (2015); the LUNGevity Foundation Face of Hope Award (2015); the Gary Neil Prize for Innovation in Drug Development from the American Society for Clinical Pharmacology and Therapeutics (2018); and the National Organization for Rare Disorders Rare Impact Award (2018).
Date and time: 09 June 2018, 8:00 am-9:00 pm
Location: One Medimmune Way (AstraZeneca/Medimmune HQ), Gaithersburg, MD 20878
Early bird registration rates end on 14 May.
Scan QR code or click/use url goo.gl/gaeEDr for registration